> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Notice of Eylea Biosimilar Patent Infringement Suit
- URL: https://www.fdaweb.com/notice-of-eylea-biosimilar-patent-infringement-suit/
- Published: 2024-07-11T12:00:00.000Z
- Updated: 2026-09-14T14:35:13.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5157330

*Federal Register* notice: FDA is providing notice that a patent infringement lawsuit has been filed against Amgen over its BLA submission for a biosimilar copy of Regeneron’s Eylea (aflibercept), indicated for treating wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The complaint is titled *Regeneron Pharmaceuticals, Inc. v. Amgen Inc.*, 2:24–CV–00264 (CA Central District — filed 1/10). The agency notes that it has only a ministerial role that is limited to publishing notice of a complaint received under section 351(l)(6)(C) of the Public Health Service Act and does not perform a substantive review of the complaint. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-07-11/pdf/2024-15237.pdf?ref=fdaweb.com).